Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03200847 · ClinicalTrials.gov registry record · Phase 1
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
A Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03200847 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 26 participants.
The verdict
NCT03200847, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is a Phase I/Ib investigator-initiated open label of the combination of VESANOID and pembrolizumab treatment.
Interventions
- DRUG Pembrolizumab with All-Trans Retinoic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-10-31 |
| Est. Completion | 2022-10-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03200847
The ClinicalTrials.gov registry entry for NCT03200847 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pembrolizumab with All-Trans Retinoic Acid is the first listed.
NCT03200847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03200847 about?
NCT03200847 is a clinical study titled "Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma". This is a Phase I/Ib investigator-initiated open label of the combination of VESANOID and pembrolizumab treatment.
What is the current status of trial NCT03200847?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2017-10-31. Estimated completion is 2022-10-19.
What interventions are being tested in trial NCT03200847?
The interventions under investigation include: Pembrolizumab with All-Trans Retinoic Acid (DRUG).
Who is sponsoring clinical trial NCT03200847?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.